The esophageal cancer risk with bisphosphonate bone drugs may be a bigger problem than thought, particularly with use of alendronate (Fosamax), an adverse event surveillance study suggested.
http://www.medpagetoday.com/HematologyOncology/OtherCancers/32992?utm_content=&utm_medium=email&utm_campaign=DailyHeadlines&utm_source=WC&eun=g424100d0r&userid=424100&email=joannenicholas@gmail.com&mu_id=5523180
ASCO: Bone Meds, Esophageal Cancers Linked